# Position statement on macroprolactinemia from the Department of Neuroendocrinology of the Brazilian Society of Endocrinology and Metabolism (SBEM) and the Brazilian Society of Clinical Pathology/Laboratory Medicine (SBPC/ML)

## TL;DR

This position statement explains how identifying macroprolactinemia can avoid unnecessary treatments and tests in patients with high prolactin levels.

## Contribution

The paper provides a joint clinical guideline on macroprolactinemia from two Brazilian medical societies.

## Key findings

- Macroprolactinemia is often misdiagnosed as hyperprolactinemia, leading to unnecessary interventions.
- Proper identification of macroprolactinemia can reduce inappropriate treatments and investigations.
- The statement outlines best practices for measuring and interpreting prolactin levels.

## Abstract

Measurement of serum prolactin levels is a common practice in clinical settings,
particularly among women of reproductive age. In cases of hyperprolactinemia,
identifying macroprolactinemia can help prevent unnecessary investigation and
inappropriate treatments. This Position Statement, jointly prepared by the
Brazilian Society of Endocrinology and Metabolism (SBEM) and the Brazilian
Society of Clinical Pathology/Laboratory Medicine (SBPC/ML), addresses several
aspects of macroprolactinemia relevant to clinical practice – including
concepts, definitions, epidemiological aspects, measurement techniques, and the
role of screening – and discusses some clinical dilemmas.